Publications & posters Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts. Filter View all EFX FGF21 MASH Jun 2018 | FROM EXTERNAL EXPERTS Recent advances in understanding and managing non-alcoholic fatty liver disease Albhaisa, S., Sanyal A. F1000 Research Feb 2018 | From External Experts LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate—G-protein couple receptor 91 (GPR91) pathway in mice Le, C.T., et al PLoS One Jan 2018 | From External Experts Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling Lee, S., et al Nature Jan 2018 | FROM EXTERNAL EXPERTS Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease Estes, C. et al. Hepatology May 2017 | FROM EXTERNAL EXPERTS A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys Stanislaus, S. et al. Endocrinology Apr 2017 | FROM EXTERNAL EXPERTS FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists Li, X. et al. Journal of Bone and Mineral Research Jan 2017 | From External Experts Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis Dulai, P et al Hepatology Nov 2016 | FROM EXTERNAL EXPERTS An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function Lee, J.H. et al. American Journal of Translational Research Page 5 of 6« First<<...23456>> We are evaluating potential treatments for MASH and other serious metabolic diseases to build our pipeline. View Our Pipeline We are evaluating potential treatments for MASH and other serious metabolic diseases to build our pipeline. View Our Pipeline